- Resmed Corp. v. Cleveland Medical Devices, Inc.All claims unpatentablePTAB · Jun 29, 2026 · IPR2025-00246 · APJ Cynthia M Hardman · IPR · Final written decision
Claims 15–29 are unpatentable as obvious over the asserted combinations; the contingent motion to amend claims 30–41 is denied for lack of written-description support.
RulingsFinal written decision- PTAB / AIA Trials › Real party in interest / privityRpi dispute resolved for petitionerDecided for petitioner
“Patent Owner filed an authorized Motion to Terminate, alleging that Petitioner failed to name its corporate parent, ResMed Inc., as a real party in interest. Paper 39. Petitioner filed an opposition. Paper 42. Patent Owner filed a reply. Paper 43. We denied the Motion to Terminate. Paper 51.” slip op. at 3
- Skill levelSkill level board ownOther
“understanding of a person of ordinary skill in the art at the time the invention was made.10 See Graham, 383 U.S. at 17–18. The parties agree that a person of ordinary skill in the art (sometimes referred to herein as “POSITA”) would have had: at least a bachelor’s degree in mechanical engineering, electrical engineering, computer science, biomedical engineering, or a similar technical field, with at least two years of relevant product design experience working with diagnostic sensor systems and network data systems, such as networked PAP machines. Additional experience could substitute for less education, and additional education could likewise substitute for less experience. Pet. 3–4 (citing Ex. 1003 (Kirkness Decl.) ¶ 44); PO Resp. 4. 9 Patent Owner does not assert any objective indicia of nonobviousness. See generally PO Resp. 10 For purposes of this Decision, we apply a priority date of November 4, 2005. See supra n.4. Because the proposed level of ordinary skill in the art is consistent with the cited prior art and is undisputed on this record, we adopt it for purposes of this Decision. See Okajima v. Bourdeau, 261 F.3d 1350, 1355 (Fed. Cir. 2001) (indicating that the prior art itself may reflect an appropriate skill level).” slip op. at 9
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther
“Patent Owner does not persuade us to construe the term as “a value [or calculated value] that indicates how dire a patient’s symptoms are.” Patent Owner points to nothing in the intrinsic record that purportedly supports this construction, and we agree with Petitioner that “the patent specification’s disclosures regarding determining a level of symptom severity are broad, establishing that it can generally be derived from any sensor data and/or breathing events.” Pet. Reply 3–4; see also Ex. 1001, 3:44–46 (“Signals from the[] sensors are then analyzed to determine the level of severity of the symptoms of the subject’s sleep disorder.”). Patent Owner relies only on expert declarations to support its construction. But as indicated by the Federal Circuit, extrinsic evidence is “less significant than the intrinsic record in determining ‘the legally operative meaning of claim language.’” Phillips v. AWH Corp., 415 F.3d 1303, 1317 (Fed. Cir. 2005). This is especially applicable here, where neither Dr. D’Ambrosio’s nor Dr. Schwartz’s declaration was prepared for this proceeding, and neither declarant was subject to cross examination on their opinions. Moreover, neither of the declarants was opining on claim construction; rather, they were addressing indefiniteness and/or written description issues. See Ex. 1058 at 7 (heading addressing definiteness); Ex. 2026 at 18 (heading addressing written description). Further, Dr. Schwartz appears to have been making an argument about certain patent claims (not the challenged ’333 patent) based on Patent Owner’s own statements made during prosecution of a separate patent application. See Ex. 2026 ¶ 47 (“[T]he similar term used in the ’284 patent claims (‘data of severity of sleep disorder symptoms’) does not find written description support in the specification by a disclosure of the same statistics disclosed in Wright, because CleveMed argued those statistics are not related to severity of sleep disorder symptoms.” (emphasis added)). Patent Owner has not persuaded us that Dr. Schwartz’s testimony has direct applicability to the claim term at issue here. Dr. Borkholder’s testimony is likewise unpersuasive. Aside from citing Dr. D’Ambrosio’s and Dr. Schwartz’s declarations, Dr. Borkholder cites Exhibits 2027 and 2016. These exhibits discuss indices such as AHI and RDI that are used to assess the severity of a patient’s symptoms, but Patent Owner has not adequately explained how they bear on construction of the claim term at issue here, which is not addressed in these exhibits. Ex. 2022 ¶¶ 32–33. Accordingly, we accord Dr. Borkholder’s claim construction opinions little weight, because they are unsupported by reference to objective, corroborating evidence of record. See, e.g., Ashland Oil, Inc. v. Delta Resins & Refractories, Inc., 776 F.2d 281, 294 (Fed. Cir. 1985) (“Lack of factual support for expert opinion going to factual determinations . . . may render the testimony of little probative value in a validity determination.”); Xerox Corp. v. Bytemark, IPR2022-00624, Paper 9, 15 (PTAB 2023) (precedential) (explaining that declaration testimony that “is conclusory and unsupported” and which “adds little to the conclusory assertion for which it is offered to support . . . is entitled to little weight”).” slip op. at 23
- Obviousness (§103) › Graham factors (scope of art, differences, level of skill)UnpatentableUnpatentable
“We find that Petitioner has the better argument. Tidal volume refers to “the volume of air that is inspired or expired during a respiratory cycle.” Ex. 2028, 13–14; PO Resp. 10. “[H]ypopnea events are defined as a reduction of ≥50 % or 74 % in tidal volume from baseline and apnea events as absence of tidal volume for at least 10s.” Ex. 2028, 13–14 (emphasis omitted). Toge teaches that a control unit analyzes collected data (e.g., the flow rate) and calculates tidal volume. Ex. 1044 (Toge) ¶¶ 34–38. The calculated tidal volume is “a quantified level of severity data based on the subject’s sleep apnea symptoms during the therapy” because it represents, e.g., the “level of airway obstruction the patient experiences during the sleep apnea treatment using the PAP device.” Pet. 15. As Dr. Chatterjee explains: Toge discloses that tidal volume Fp is a quantified level of data because Toge discloses that Fp is monitored with respect to threshold values (id., [0051]) and because Fp is a function of Ft, Fa, and Fb, which are quantitative values. Toge discloses that tidal volume Fp is severity data because Toge discloses that tidal volume is indicative of whether the patient’s breathing warrants “emergency measures” (id., [0039]) and whether to “send an alert” in “an emergency where the patient’s breathing has drastically weakened” (id., [0055]). . . . . Because Toge discloses determining tidal volume (determine a quantified level of severity data) based on Ft, Fa, and Fb (id., [0035]), which corresponds to the subject’s condition (subject’s sleep apnea symptoms) while using the device (during the therapy) (id., [0036], [0037]), Toge discloses determin[ing] a quantified level of severity data based on the subject’s sleep apnea symptoms during the therapy. Ex. 1005 (Chatterjee Decl.) ¶¶ 122–125. Patent Owner’s attempt to dismiss tidal volume as a mere “breathing metric” is unavailing. First, Petitioner correctly “notes that in the paragraph PO cites to in Dr. Schwartz’s declaration, he indicates that breathing metrics are a level of severity data.” Pet. Reply 8 (citing Ex. 2026 ¶ 46 (“standard sleep disordered breathing metrics” [ ] were well validated indicators of the type and severity of sleep disordered breathing”)). Second, Dr. Kirkness explains that tidal volume represents the level of airway obstruction, e.g., apnea “is the most severe form of reduction in airflow [and] the absence of airflow results in quantified tidal volume of zero milliliters per breath.” Ex. 1003 (Kirkness Decl.) ¶¶ 157, 159; see also PO Resp. 10–11 (Patent Owner recognizing that an apnea is defined as absence of tidal volume for at least 10 seconds). The calculated tidal volume thus indicates severity because it is used to adjust the PAP system, e.g., in the case of decreasing tidal volume, a medical professional can change the airflow settings “to counter/treat the more severe level of airway obstruction observed from the decreasing tidal volume.” Ex. 1003 (Kirkness Decl.) ¶ 158; Pet. 15–16; Ex. 1044 (Toge) ¶ 39.” slip op. at 26
Patent outcomesUS 11,857,333 unpatentableClaim construction§ 103 obviousnesscites KSR · GrahamPatents in suitUS 11,857,333 - Røde Microphones, LLC / Freedman Electronics Pty Ltd. v. Zaxcom, Inc.No claims unpatentablePTAB · Jun 11, 2026 · IPR2025-00232 · APJ Miriam L Quinn · IPR · Final written decision
The Board held that Petitioner did not prove any challenged claims of the ’207 patent unpatentable under the Strub, Woo, Nagai, and Gleissner obviousness ground.
RulingsFinal written decision- Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITAPlain and ordinary meaningDecided for patent owner
“in these respects. The preambles of claims 17 and 59 recite the “audio device wearable by a user for storing locally generated audio.” There is neither mention of “multi-track” audio in the claim, nor is the audio device limited to capturing a single source of sound, such as a single performer. Accordingly, we are not persuaded that the ’443 and ’207 patent claims support the limited scope that Patent Owner urges for the term “locally generated audio.” None of Patent Owner’s citations to the specification define or require that the “locally generated audio” correspond to audio generated only by a single performer. See, e.g., 230 IPR, Ex. 1001, 8:59−62 (stating that the local audio input device “may be worn by the performer and connects to local audio device 102 at local audio input device port 314”). Patent Owner’s argument that the specification “teaches a single creator/performer per local audio device” is well-taken, but the teachings do not indicate the intent to exclude other sounds from being captured at the local audio device (or indicate how the device would prevent the capture of other sounds, such that the audio would be “isolated” as Patent Owner contends). See 230 Sur-Reply 10 (citing 230 IPR, Ex. 1001, 4:28−32, 10:29−34, and Insituform Techs., Inc. v. Cat Contr., Inc., 99 F.3d 1098, 1105 (Fed. Cir. 1996) (“[C]laim 1 refers to ‘a cup’ and ‘the cup’ repeatedly, suggesting that only one cup is involved . . . . [N]either the specification nor the drawings disclose the use of more than one cup.”)). For instance, the specification describes that the “independent track of audio is received from one of the performer’s local audio device 102.” 230 IPR, Ex. 1001, 10:33−34. Thus, in this description the audio track corresponds to the audio captured by a particular audio device—which was worn by the performer— but does not limit that captured audio to only sounds made by the performer. As to the “local audio data” term, Patent Owner argues that “audio data” means “mono or stereo audio files created from independent, isolated locally generated audio files, such files suitable for creation of a multi-track audio file.” 230 PO Resp. 9−10 (citing Ex. 2140 ¶¶ 131, 134). This argument is unsupported by the claim language or specification. The claim does not require the creation of audio files, much less a “multi-track audio file.” The specification describes storing audio files in memory without the specificity that Patent Owner urges we adopt. See 230 IPR, Ex. 1001, 13:1−14. Accordingly, we are not persuaded by Patent Owner’s proposed construction of “local audio data.” Rather, we understand “audio data” to have a plain and ordinary meaning, such as the one given to the term by the District Court in the underlying litigation. 230 IPR, Ex. 1037, 10. We adopt the District Court’s construction of “audio data” to mean “data comprising audio signals in digital form.” Id. This finds support in the specification as the audio is described as being converted into digital audio and stored in a file. See 230 IPR, Ex. 1001, 13:1−14. Our conclusion is consistent with the plain and ordinary meaning of the term as that would be understood by a person of ordinary skill in the art, and we see no reason to deviate from the conclusions of the District Court on this point.” slip op. at 20
- Prior constructionPrior construction adoptedDecided for petitioner
“data” means “mono or stereo audio files created from independent, isolated locally generated audio files, such files suitable for creation of a multi-track audio file.” 230 PO Resp. 9−10 (citing Ex. 2140 ¶¶ 131, 134). This argument is unsupported by the claim language or specification. The claim does not require the creation of audio files, much less a “multi-track audio file.” The specification describes storing audio files in memory without the specificity that Patent Owner urges we adopt. See 230 IPR, Ex. 1001, 13:1−14. Accordingly, we are not persuaded by Patent Owner’s proposed construction of “local audio data.” Rather, we understand “audio data” to have a plain and ordinary meaning, such as the one given to the term by the District Court in the underlying litigation. 230 IPR, Ex. 1037, 10. We adopt the District Court’s construction of “audio data” to mean “data comprising audio signals in digital form.” Id. This finds support in the specification as the audio is described as being converted into digital audio and stored in a file. See 230 IPR, Ex. 1001, 13:1−14. Our conclusion is consistent with the plain and ordinary meaning of the term as that would be understood by a person of ordinary skill in the art, and we see no reason to deviate from the conclusions of the District Court on this point.” slip op. at 21
- Obviousness (§103) › Objective indicia / secondary considerations › Skepticism / industry praiseObjective indicia with nexusDecided for patent owner
“1. Industry Praise: Academy and Emmy Awards Patent Owner argues that it “revolutionized [the] industry with the” slip op. at 97
- Obviousness (§103) › Objective indicia / secondary considerations › Long-felt need / failure of othersDecided for patent owner
“2. Long-Felt Need Patent Owner further proffers the testimony of two witnesses as” slip op. at 104
Patent outcomesUS 10,276,207 not shown unpatentableClaim construction§ 103 obviousnesscites Phillips · GrahamPatents in suitUS 10,276,207 - Røde Microphones, LLC / Freedman Electronics Pty Ltd. v. Zaxcom, Inc.No claims unpatentablePTAB · Jun 11, 2026 · IPR2025-00230 · APJ Miriam L Quinn · IPR · Final written decision
The Board determined that Petitioner had not shown any challenged claims of the ’443 or ’207 patents unpatentable, including under the asserted obviousness grounds.
RulingsFinal written decision- Expert testimonySkill level petitioner adoptedOther
“E. Level of Ordinary Skill in the Art Based on the argument and evidence presented in the Petition and Patent Owner’s preliminary response, we determined, as stated in our Decision on Institution, that “a person of ordinary skill in the art would have had a Bachelor’s degree in electrical engineering and two or more years of experience working with audio and wireless communications systems.” 230 Dec. on Inst. 16; 232 Dec. on Inst. 22−23. Patent Owner reiterates its position that a person of ordinary skill the art would have had “a bachelor’s degree in electrical engineering or a related subject and two to five years’ experience working with multi-track audio and wireless communications systems in the professional performance industry.” 230 IPR, PO Resp. 6−7 (emphasis added) (identical passage in 232 PO Resp. 8). Thus, the dispute centers on whether the level or ordinary skill includes specific work experience with multi-track audio in the professional performance industry. We do not agree that this specific work experience is necessary to the level of ordinary skill in the instant proceedings. In determining whether an invention would have been obvious at the time it was made, we consider the level of ordinary skill in the pertinent art at the time of the invention. Graham v. John Deere, 383 U.S. 1, 17−18 (1966). “The importance of resolving the level of ordinary skill in the art lies in the necessity of maintaining objectivity in the obviousness inquiry.” Ryko Mfg. Co. v. Nu‑Star, Inc., 950 F.2d 714, 718 (Fed. Cir. 1991). The “person of ordinary skill in the art” is a hypothetical construct, from whose vantage point obviousness is assessed. In re Rouffet, 149 F.3d 1350, 1357 (Fed. Cir. 1998). In determining the level or ordinary skill, we may consider various factors including “type of problems encountered in the art; prior art solutions to those problems; rapidity with which innovations are made; sophistication of the technology; and educational level of active workers in the field.” In re GPAC, 57 F.3d 1573, 1579, (Fed. Cir. 1995) (quoting Custom Accessories, Inc. v. Jeffrey-Allan Indus., Inc., 807 F.2d 955, 962 (Fed. Cir. 1986)). Patent Owner’s proposed specificity of work with multi-track audio in a professional performance industry is not supported by the record. First, Patent Owner submits conclusory declaration testimony of James DeFilippis—repeating verbatim, and without any supported reasoning, Patent Owner’s proposed level of ordinary skill. Ex. 2140 ¶ 15. As such, the testimony is not persuasive. Second, Patent Owner’s additional declaration testimony of Jack” slip op. at 12
- Prior constructionPrior construction adoptedDecided for petitioner
“data” means “mono or stereo audio files created from independent, isolated locally generated audio files, such files suitable for creation of a multi-track audio file.” 230 PO Resp. 9−10 (citing Ex. 2140 ¶¶ 131, 134). This argument is unsupported by the claim language or specification. The claim does not require the creation of audio files, much less a “multi-track audio file.” The specification describes storing audio files in memory without the specificity that Patent Owner urges we adopt. See 230 IPR, Ex. 1001, 13:1−14. Accordingly, we are not persuaded by Patent Owner’s proposed construction of “local audio data.” Rather, we understand “audio data” to have a plain and ordinary meaning, such as the one given to the term by the District Court in the underlying litigation. 230 IPR, Ex. 1037, 10. We adopt the District Court’s construction of “audio data” to mean “data comprising audio signals in digital form.” Id. This finds support in the specification as the audio is described as being converted into digital audio and stored in a file. See 230 IPR, Ex. 1001, 13:1−14. Our conclusion is consistent with the plain and ordinary meaning of the term as that would be understood by a person of ordinary skill in the art, and we see no reason to deviate from the conclusions of the District Court on this point.” slip op. at 21
- ExcludeMotion to exclude, deniedDenied
“irrelevant under Federal Rules of Evidence 401–403. Patent Owner asserts that Petitioner has failed to establish that these documents reflect the understanding of a person of ordinary skill in the art, or that they are consumer-oriented documents, but not technical references or sources for understanding the meaning of claim terms. 230 IPR, Paper 64, 3−4. According to Patent Owner, these exhibits lack a “technical foundation” that establishes the technical meaning of a claim term. Id. We do not agree with Patent Owner as it conflates relevance with sufficiency of evidence to prove a contention on claim construction. Dictionary definitions are often useful when determining a claim term’s plain and ordinary meaning in the context of the specification, and as such are relevant when claim terms are disputed. Phillips, 415 F.3d at 1312. Furthermore, the evidence of record shows testimony as to whether the “Sweetwater” glossary entry for “body pack” would be relevant to the meaning of the term in the “world of wireless performance.” 230 IPR, Paper 67, 4 (citing Ex. 1073 ¶ 42). Patent Owner’s objections are overruled as to relevance.” slip op. at 116
- BurdenFwd all claims patentableNot shown unpatentable
“after a full and fair hearing, we determine that Petitioner has not demonstrated by a preponderance of the evidence that any of the challenged claims are unpatentable.” slip op. at 125
Patent outcomesUS 7,711,443 not shown unpatentableClaim construction§ 103 obviousnesscites Phillips · GrahamPatents in suitUS 7,711,443 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00740 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Patent Owner’s motions to dismiss and entered adverse judgment after Patent Owner disclaimed all challenged claims in the captioned trials.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018).” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied
“Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
NonePatents in suitUS 10,828,559 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00703 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Patent Owner’s motions to dismiss and entered adverse judgment against it on claims 1, 2, 11, and 13 of the challenged patent after their disclaimer.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied
“In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
- PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)InstitutedInstituted
“above-captioned cases requesting inter partes review of certain claims (“the challenged claims”) of the subject U.S. Patents. See, e.g., IPR2025-00702, Paper 1. Mullen Industries LLC (“Patent Owner”) filed Preliminary Responses to the Petitions. See, e.g., IPR2025-00702, Paper 10. Because we determined that Petitioner had demonstrated a reasonable likelihood that it would prevail with respect to at least one challenged claim in each case, we instituted inter partes review of all challenged claims on all asserted grounds in all of the cases. See, e.g., IPR2025-00702, Paper 11.” slip op. at 2
NonePatents in suitUS 11,033,821 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00702 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Mullen’s motions to dismiss and entered adverse judgment after Mullen disclaimed all challenged claims in the instituted trials.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018).” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Motion to exclude, deniedDenied
“Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
NonePatents in suitUS 10,967,270 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00737 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Mullen’s motions to dismiss and entered adverse judgment against it on claims 1, 2, 4-7, 13, and 17 after those claims were disclaimed post-institution.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“We determine that Petitioner has the better position. Our rules provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied
“Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
NonePatents in suitUS 8,585,476 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00738 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Patent Owner’s motions to dismiss and entered adverse judgment after Patent Owner disclaimed all challenged claims, including claims 1, 2, 11, and 13 of the ’582 patent.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018).” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied
“In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
NonePatents in suitUS 9,744,448 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00739 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Mullen’s motions to dismiss and entered adverse judgment against it for challenged claims 1, 8, 13, and 20 of U.S. Patent 10,179,277 after their post-institution disclaimer.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“We determine that Petitioner has the better position. Our rules provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied
“In the Motions, Patent Owner, relying on Sanofi-Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., argues that, “[b]ecause all claims at issue have been disclaimed, any case or controversy over the claims is moot,” and, “[a]ccordingly, the IPR[s] should be dismissed.” Mot. 2 (citing Sanofi- Aventis U.S., LLC v. Dr. Reddy’s Lab’ys, Inc., 933 F.3d 1367, 1373 (Fed. Cir. 2019)). Sonofi-Aventis pertains to the requirement under Article III of the Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
NonePatents in suitUS 10,179,277 - Meta Platforms, Inc. v. Mullen Industries LLCAdverse judgmentPTAB · Dec 19, 2025 · IPR2025-00741 · APJ Ken B Barrett · IPR · Adverse judgment
The Board denied Patent Owner’s dismissal motions and entered adverse judgment against Mullen Industries LLC on claims 1, 12, 17, and 20 of U.S. Patent 11,376,493 B2 after disclaimer.
RulingsAdverse judgment- Adverse judgmentAdverse judgmentGranted
“provide that “[a] party may request judgment against itself at any time during a proceeding,” and “[a]ctions construed to be a request for adverse judgment include . . . [c]ancellation or disclaimer of a claim such that the party has no remaining claim in the trial.” 37 C.F.R. § 42.73(b)(2). “The application of the [adverse judgment] rule on its face does not turn on the patentee’s characterization of its own request.” Arthrex, Inc. v. Smith & Nephew, Inc., 880 F.3d 1345, 1349 (Fed. Cir. 2018). In this case, Patent Owner, after the institution decisions, disclaimed the challenged claims such that there are no remaining claims in the trials. Patent Owner presents no persuasive reasons why we should not apply Rule 42.73 or why termination or dismissal is more appropriate. Under the IPR2025-00745 (Patent 9,662,582 B2) IPR2025-00746 (Patent 10,974,151 B2) circumstances of these cases, we construe the filing of disclaimers as requests for adverse judgment.” slip op. at 6
- PTAB / AIA Trials › Other PTAB motions (exclude, strike, seal, additional discovery, rehearing)Denied
“Constitution that there exist a case or controversy to be adjudicated by a district court. See Sanofi-Aventis, 933 F.3d at 1372–73. The Board is not a district court or any other Article III court, and Patent Owner has not shown persuasively that Sanofi-Aventis supports its argument that dismissal, as opposed to adverse judgement, is appropriate.” slip op. at 3
NonePatents in suitUS 11,376,493
Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.